Consensus for the management of patients with type 2 diabetes in combination with cardiorenal diseases

Mankovsky B. M., Bilchenko O. V., Zinych O. V., Ivanov D. D., Irkin O. I., Komisarenko Yu. I., Kushnirenko S. V., Lutay Ya. M., Mishchenko L. A., Pertseva N. O., Protsiuk O. V., Saenko Ya. A., Smirnov I. I., Sokolova L. K., Urbanovych A. M., Yuzvenko T. U., Yagensky A. V.

Abstract

Diabetes mellitus is a global medical and social problem due to the ever-increasing number of people suffering from this disease and the high risk of developing disabling micro- and macrovascular and neurological complications, which leads to a significant increase in mortality and a reduction in the life expectancy of patients. On the other hand, both diabetes and chronic kidney disease lead to a two-fold increase in the risk of cardiovascular disease, and in the case of the combined development of diabetes and kidney damage, the cardiovascular risk increases even more (Virani et al., 2021).

At the same time, the approaches to the therapy of these patients often differ among doctors of different specialties. Thus, endocrinologists pay the greatest attention to the correction of metabolic disorders, cardiologists to changes in hemodynamic indicators, nephrologists to the state of kidney function, while in many cases there is no general approach to the management of such patients.

Taking into account the multidisciplinary nature of the problem of diabetes, we consider it necessary to create general recommendations of specialists in various fields of medicine for the treatment of patients with type 2 diabetes and cardiorenal diseases, which would be based on the results of modern large multicenter clinical studies conducted from the positions and according to the requirements of leading European and world scientific societies, which would take into account the medical, organizational and socio-economic realities of our country, would be possible for doctors of various specialties in different regions of the country to perform. In order to develop such recommendations, a group of experts representing this Consensus was created under the auspices of the Ukrainian Diabetes Association.

The main goal of these recommendations is to prevent new cases of atherosclerotic cardiovascular diseases, the development and progression of heart failure, and chronic kidney disease through the use of modern therapeutic options.

Keywords: type 2 diabetes, cardiovascular diseases, kidney diseases, prediabetes, prevention.

References

1. IDF Diabetes Atlas 2021 – 10th edition diabetesatlas.org Accessed 01 August 2022
2. Yehuda Handelsman,, John E. Anderson, George L. Bakris, Christie M. Ballantyne, Joshua A. Beckman, Deepak L. Bhatt, Zachary T. Bloomgarden, Biykem Bozkurt, Matthew J. Budoff, Javed Butler, Samuel Dagogo-Jack, Ian H. de Boer, Ralph A. DeFronzo, Robert H. Eckel, Daniel Einhorn, Vivian A. Fonseca, Jennifer B. Green, George Grunberger, Chris Guerin, Silvio E. Inzucchi, Paul S. Jellinger, Mikhail N. Kosiborod, Pamela Kushner, Norman Lepor, Christian W. Mende, Erin D. Michos, Jorge Plutzky, Pam R. Taub, Guillermo E. Umpierrez, Muthiah Vaduganathan, Matthew R. Weir. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications 36 (2022) 108101
3. Centers for Disease Control and Prevention. Chronic kidney disease surveillance system—United States; https://nccd.cdc.gov/CKD/. Accessed 19 November 2019.
4. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. Endocr Pract. 2020;26:107–139.
5. Kidney, Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98, s1-s115.
6. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics—2021 update: a report from the American Heart Association. Circulation. 2021;143: e254–e743.
7. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes—2022. Diabetes Care. 2022;45, S144-s174.
8. American Diabetes Association. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45, S113-s124.
9. Diabetes Prevention Program Research Group, Ratner R, Goldberg R. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005;28:888–894.
10. STOP-NIDDM Trial Research Group, Chiasson JL, Josse RG, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077.
11. DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes preventionin impaired glucose tolerance. N Engl J Med. 2011;364:1104–1115.
12. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008.
13. Papaetis GS. Liraglutide therapy in a prediabetic state: rethinking the evidence. Curr Diabetes Rev. 2020;16:699–715.
14. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the american College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73: e285–e350.
15. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1–87.
16. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
17. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. 2014; 384:626–635.
18. Elam M, Lovato L, Ginsberg H. The ACCORD-lipid study: implications for

treatment of dyslipidemia in type 2 diabetes mellitus. Clin Lipidol. 2011;6:9–20.

19. Ginsberg HN. The ACCORD (Action to control cardiovascular risk in Diabetes) lipid trial: what we learn from subgroup analyses. Diabetes Care. 2011;34:S107–S108.
20. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
21. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol.2018;71, e127.
22. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the european Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021–3104.
23. Group ASC, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529–1539.
24. Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. 2019;394:1169–1180.
25. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–851.
26. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
27. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
28. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebocontrolled Lancet. 2019;394:121–130.
29. Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392: 1519–1529.
30. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323–334.
31. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
32. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
33. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–357.
34. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117–128.
35. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129–139.
36. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306.
37. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–1435.
38. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–1461.
39. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424.
40. Nassif ME, Windsor SL, Tang F, et al. Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation. 2019;140:1463–1476.
41. Heerspink HJL, Stef´ansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446.
42. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279–1289.
43. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–1331.
44. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care. 2022;44, S125-s143.
45. American Diabetes Association. Glycemic targets: standards of medical care in diabetes—2022. Diabetes Care. 2022;45, S83-s96.
46. Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. 2013;347, f4533.
47. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35:1897–1901.
48. Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab. 2018;20:488–496.
49. Bhatt DL, Brinton EA, Miller M, et al. 4-LB: substantial cardiovascular benefit from icosapent ethyl in patients with diabetes: REDUCE-IT DIABETES. 2020; 69:4-LB.
50. Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L. Aspirin in the primary and secondary prevention of vascular disease: collaborative metaanalysis of individual participant data from randomised trials. 2009;373: 1849–1860.
51. Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinicalpractice guidelines and the Heart Failure Society of America. 2017;136: e137–e161.
52. Berg DD, Wiviott SD, Scirica BM, et al. Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes Circulation. 2019;140:1569–1577.
53. Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. J Am Soc Nephrol. 2017;28: 2263–2274.
54. Delgado C, Baweja M, Crews DC, Eneanya ND, Gadegbeku CA, Inker LA, Mendu ML, Miller WG, Moxey-Mims MM, Roberts GV, St Peter WL, Warfield C, Powe NR. A unifying approach for GFR estimation: recommendations of the NKFASN task force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis; 2021 Sep 22. S0272-6386(21)00828-3 https://doi.org/10.1053/j. 2021.08.003. Epub ahead of print. PMID: 34563581.
55. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a metaanalysis. JAMA Cardiol. 2021;6:148–158.
56. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and metaanalysis. Lancet Diabetes Endocrinol. 2019;7:845–854.
57. Zoungas S, de Boer IH. SGLT2 inhibitors in diabetic kidney disease. Clin J Am Soc 2021;16:631–633.
58. Packer M, Butler J, Zannad F, et al. Empagliflozin and major renal outcomes in heart failure. N Engl J Med. 2021;385:1531–1533.
59. Michos ED, Tuttle KR. GLP-1 receptor agonists in diabetic kidney disease. Clin J Am Soc Nephrol. 2021;16:1578–1580.
60. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–2229.
61. Pitt B, Filippatos G, Agarwal R. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021 Aug 28. https://doi.org/10.1056/NEJMoa2110956. Online ahead of print.
62. Agarwal R, Filipattos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J; 2021 Nov 22. Online ahead of print https://doi.org/10.1093/eurheartj/ehab777.
63. Mullens W, Damman K, Testani JM, et al. Evaluation of kidney function throughout the heart failure trajectory—a position statement from the heart failure Association of the European Society of cardiology. Eur J Heart Fail. 2020;22:584–603.
64. Davies M, Chatterjee S, Khunti K. The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies. Clin Pharmacol. 2016;8:61–81.
65. Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract. 2016;22:753–762.
66. Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, Knoll GA, Muntner P, Pecoits-Filho R, Sarnak MJ, Tobe SW, Tomson CRV, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli M, Cheung M, Earley A, Mann JFE. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021 Mar;99(3):559-569. doi: 10.1016/j.kint.2020.10.026. PMID: 33637203.
67. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney inter., Suppl. 2013; 3: 1–150.
68. Li Shen, Pardeep Singh Jhund, Kieran Francis Docherty, Muthiah Vaduganathan, Mark Colquhoun Petrie, Akshay Suvas Desai, Lars Køber, Morten Schou, Milton Packer, Scott David Solomon, Xingwei Zhang, John Joseph Valentine McMurray. Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 27, 2573–2587.